Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) EBIT (2022 - 2025)

Historic EBIT for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' EBIT fell 976.23% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.9 million, marking a year-over-year increase of 1716.02%. This contributed to the annual value of -$9.7 million for FY2024, which is 8847.17% down from last year.
  • According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' EBIT is -$2.3 million, which was down 976.23% from -$1.6 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year EBIT high stood at -$215116.0 for Q3 2022, and its period low was -$4.2 million during Q2 2024.
  • For the 4-year period, 60 Degrees Pharmaceuticals' EBIT averaged around -$1.6 million, with its median value being -$1.6 million (2023).
  • In the last 5 years, 60 Degrees Pharmaceuticals' EBIT plummeted by 60741.46% in 2023 and then surged by 6168.72% in 2025.
  • 60 Degrees Pharmaceuticals' EBIT (Quarter) stood at -$684698.0 in 2022, then tumbled by 176.64% to -$1.9 million in 2023, then dropped by 9.02% to -$2.1 million in 2024, then fell by 12.61% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.9 million during Q1 2025.